Objectives: The concentration in plasma of the brain-specific cholesterol metabolite cerebrosterol has been proposed as a biomarker of neurodegeneration in multiple sclerosis (MS) and other neurological diseases. It is unknown, however, which pathophysiological process in MS best accounts for variations in plasma cerebrosterol. Patients and methods: In this study, we related plasma cerebrosterol concentrations in 46 MS patients - 27 with a relapsing-remitting (RR) disease course and 19 with a primary progressive (PP) course - to three conventional magnetic resonance imaging measures: on T1-weighted brain scans, volume of gadolinium-enhanced lesions (a marker of active inflammation) and hypointense lesions (a marker of edema or axonal loss) and on T2-weighted scans, volume of hyperintense lesions (a marker of disease extent). Results: By multiple-regression analysis, we uncovered negative correlations between the cerebrosterol-cholesterol ratio in plasma and both age at sampling (β = -0.35 and p = 0.079 in RRMS; β = -0.76 and p = 0.006 in PPMS) and volume of T2-weighted lesions (β = -0.52 and p = 0.078 in RRMS; β = -0.50 and p = 0.247 in PPMS). Conclusion: We hypothesize that decreases in plasma cerebrosterol may reflect the total spatiotemporal burden of MS-the cumulative effects of its dissemination in space and its duration in time.

Danylaitè Karrenbauer, V., Leoni, V., Lim, E., Giovannoni, G., Ingle, G., Sastre-Garriga, J., et al. (2006). Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis. CLINICAL NEUROLOGY AND NEUROSURGERY, 108(5), 456-460 [10.1016/j.clineuro.2005.07.010].

Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis

Leoni V;
2006

Abstract

Objectives: The concentration in plasma of the brain-specific cholesterol metabolite cerebrosterol has been proposed as a biomarker of neurodegeneration in multiple sclerosis (MS) and other neurological diseases. It is unknown, however, which pathophysiological process in MS best accounts for variations in plasma cerebrosterol. Patients and methods: In this study, we related plasma cerebrosterol concentrations in 46 MS patients - 27 with a relapsing-remitting (RR) disease course and 19 with a primary progressive (PP) course - to three conventional magnetic resonance imaging measures: on T1-weighted brain scans, volume of gadolinium-enhanced lesions (a marker of active inflammation) and hypointense lesions (a marker of edema or axonal loss) and on T2-weighted scans, volume of hyperintense lesions (a marker of disease extent). Results: By multiple-regression analysis, we uncovered negative correlations between the cerebrosterol-cholesterol ratio in plasma and both age at sampling (β = -0.35 and p = 0.079 in RRMS; β = -0.76 and p = 0.006 in PPMS) and volume of T2-weighted lesions (β = -0.52 and p = 0.078 in RRMS; β = -0.50 and p = 0.247 in PPMS). Conclusion: We hypothesize that decreases in plasma cerebrosterol may reflect the total spatiotemporal burden of MS-the cumulative effects of its dissemination in space and its duration in time.
Articolo in rivista - Articolo scientifico
oxysterols, mass spectrometry, metabolomics, neurodegenerative diseases
English
2006
108
5
456
460
reserved
Danylaitè Karrenbauer, V., Leoni, V., Lim, E., Giovannoni, G., Ingle, G., Sastre-Garriga, J., et al. (2006). Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis. CLINICAL NEUROLOGY AND NEUROSURGERY, 108(5), 456-460 [10.1016/j.clineuro.2005.07.010].
File in questo prodotto:
File Dimensione Formato  
Pl24OHC and MRI in MS KarrenubauerCNN2006.pdf

Solo gestori archivio

Dimensione 124.1 kB
Formato Adobe PDF
124.1 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/297958
Citazioni
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 30
Social impact